Genencor scales back health care activities
As previously announced, Danisco has been working to spin off Genencor's health care activities. It has now been decided to divest the product portfolio rather than spin it off into a company with Danisco as a co-shareholder.
The decision results in an immediate reduction in force in Genencor affecting 22 positions and leaving 31 positions in the health care business. To ensure and support a divestment, focus will mainly be on the sections of the project portfolio that carry sales potential. This process is expected to be finalised in the months ahead.
During the transition period, Genencor will continue development activities for GCR-8015 (preclinical) and GCR-3888 (clinical), two compounds for hematologic malignancies.
The net restructuring costs involved were included in the previously announced special items for Genencor in 2005/06 totalling approximately DKK 300 million.
Most read news
Other news from the department business & finance
These products might interest you

MS-Präzisionswaagen by Mettler-Toledo
Trusted Results at Your Fingertips
Capacity from 320 g to 12.2 kg, readability from 1 mg to 100 mg

Carepacs by Mettler-Toledo
Professional CarePacs for smooth routine testing
Tweezers, gloves and other accessories for professional weight handling

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.